← Companies|Nobel Ilac
No

Nobel Ilac

Istanbul TRFounded 19643,500 employees
Private CappharmaPrivateOncologyRespiratory
Platform: Turkish Generic
Market Cap
N/A
All Drugs
3
Clinical Trials
9
Failed / Terminated
0
FDA Approved
2
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
RimabrutinibNOB-3582Phase 12Bispecific AbIL-13PD-L1iMyelofibrosisAtopic Derm
NOB-8652NOB-8652Approved3ASOMETVEGFiWMSchizophrenia
PolalemzoparlimabNOB-2280Approved4DegraderGPRC5DWEE1iHemophilia AOCD
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (8)
2026-09-08
NOB-8652 Ph3 Readout
WM
Ph3 Readout
2026-09-24
Polalemzoparlimab Ph3 Readout
Hemophilia A
Ph3 Readout
2027-03-01
Polalemzoparlimab Ph3 Readout
OCD
Ph3 Readout
2027-08-10
Rimabrutinib Interim
Myelofibrosis
Interim
2029-06-15
Rimabrutinib Interim
PV
Interim
2030-05-14
Polalemzoparlimab Ph3 Readout
MDD
Ph3 Readout
2030-06-25
Polalemzoparlimab Ph3 Readout
Hemophilia A
Ph3 Readout
2031-05-23
NOB-8652 Ph3 Readout
Schizophrenia
Ph3 Readout